On May 15, 2014, Canadian Solar Inc. (NASDAQ:CSIQ)announced that it is scheduled to attend FBR Energy Technology Summit on Wednesday May 28, 2014 at the Grand Hyatt New York hotel and Cowen and Company 42nd Annual Technology, Media & Telecom Conference on Thursday May 29, 2014 at the New York Palace Hotel in New York City. Canadian Solar Inc. (NASDAQ:CSIQ) stock opened today at $26.79 and is currently trading at $25.04. The stock showed a negative weekly performance of -1.17%.
Mizuho believes Clovis Oncology Inc (NASDAQ:CLVS)’ early data for CO-1686 is encouraging compared to AstraZeneca’s (AZN) AZD9291. The firm has some concerns around the safety profile for AZD9291. Mizuho says results from Clovis’ key ASCO abstract confirmed promising initial data for CO-1686 in NSCLC. Clovis Oncology Inc (NASDAQ:CLVS) stock opened today at $55.11 and is currently trading at $57.81. The stock showed a positive weekly performance of 0.39%.
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), is providing an overview of its three clinical development programs and financial results for the quarter ended March 31, 2014. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $0.89, in current trading session and currently is at $0.89, by gaining 16.90%. The 52 week range of $0.31 – $1.85. Company’s market capitalization is $178.30 million.
Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) are up after Needham upgraded the specialty pharmaceutical company to “strong buy” from “buy,” saying its acquisition of Treximet was a “game changer.” Pernix Therapeutics Holdings Inc (NASDAQ:PTX) stock is open at $5.98. The EPS of the stock is -0.70. Company’s market capitalization is $225.38 million.
On May 14, 2014, MannKind Corporation (NASDAQ:MNKD) In the U.S. alone, roughly 1 of 12 people are managing diabetes. China has approximately 100 million diabetic patients as of 2012 statistics. Total global insulin sales have grown an average of $4 billion a year between 2011 and 2012 ($16.8B in 2011 and $20.8B in 2012). However, in 2013, sharp price increases sent the total market up to $35 billion. By 2018, total insulin sales are expected to increase 66% to reach more than $58 billion due to continued increase in price and patients. MannKind Corporation (NASDAQ:MNKD) stock opened the session at $7.10, and now is at $6.94. The 52 week range of the MNKD stock remained $3.80 – $8.70 and the day range was $6.91 – $7.14.